CHP Sainte Marie Osny
- Address
- lock Available on a paid plan
Neoplasms – Cancer Treatment Innovation
The site focuses on advanced therapies for several solid tumors, including HER2‑positive breast cancer. Researchers also study prostate cancer and head‑and‑neck squamous cell carcinoma. The goal is to test treatment de‑escalation, combine radiation with novel agents, and improve long‑term survival.
- Therapeutic de‑escalation strategies in HER2‑positive breast cancer
- Integration of targeted agents with radiotherapy for prostate cancer
- Immunotherapy combined with chemoradiation in head‑and‑neck cancers
- Evaluation of novel checkpoint inhibitor combinations
The multidisciplinary team of three investigators oversees seven active trials, emphasizing patient‑centered outcomes and the use of biomarkers such as circulating tumor DNA.
Digestive System Diseases – Anal and Oral Cavity Cancer Trials
Clinical research at CHP Sainte Marie Osny includes studies on anal squamous cell carcinoma. Additional trials address oral cavity and head‑and‑neck squamous cell carcinoma. Researchers aim to improve chemoradiotherapy protocols and assess new immunotherapy regimens.
- Induction chemotherapy followed by chemoradiation for advanced anal cancer
- Comparison of standard cisplatin‑radiotherapy versus immunotherapy‑enhanced approaches in head‑and‑neck SCC
- Evaluation of avelumab‑cetuximab combined with radiotherapy as a first‑line option
- Assessment of disease‑free survival with nivolumab added to cisplatin‑radiotherapy
By leveraging advanced imaging and molecular testing, the site aims to personalize treatment while maintaining safety for patients across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHP Sainte Marie Osny
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin (XXL study) | Groupe Oncologie Radiotherapie Tete Cou | Phase III | Not Recruiting | Dec 2023 | Sep 2024 |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 3 | Unknown | 2017-09-14 | 2024-02-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.